How are energy investors positioned?
Introduction & Market Context
Detection Technology OY (HLSE:DETEC) shares plunged 9.23% on April 24, 2025, after the company presented its Q1 2025 business review showing declining sales and significantly compressed margins. The Finland-based X-ray imaging solutions provider reported a 2.0% year-over-year decrease in net sales to €22.2 million, while EBITA fell sharply to €1.4 million from €2.3 million in the same period last year.
The company also revised its outlook downward, now expecting stable year-on-year sales in Q2 and Q3 2025, a significant change from previous expectations of double-digit growth. This revision was attributed to exchange rate changes and delays in security system deployments.
Quarterly Performance Highlights
Detection Technology’s Q1 2025 results revealed divergent performance across its business segments. While the medical segment showed robust growth, the security segment experienced a significant decline, and the industrial segment posted modest growth.
As shown in the following chart of key financial metrics for Q1 2025:
The company’s EBITA margin compressed significantly to 6.3% from 10.0% in Q1 2024, falling well below the company’s medium-term target of 15%. Earnings per share halved to €0.05 from €0.11 in the prior year period.
The quarterly sales trend shows relatively stable performance over recent quarters, with the Q1 2025 results representing a slight decline from the previous year:
The operating margin (EBITA) chart illustrates the significant compression in profitability compared to previous quarters, with Q1 2025 showing the lowest margin since Q2 2022:
Detailed Financial Analysis
Detection Technology’s business is heavily concentrated in the Asia-Pacific region, which accounted for 71.8% of Q1 2025 sales. The regional breakdown reveals significant challenges in the EMEIA (Europe, Middle East, India, Africa) market, which saw a 12.2% decline in sales:
By application segment, medical applications represented nearly half of the company’s business at 48.7%, showing strong 13.7% growth as the anti-corruption campaign in China eased. However, the security segment, which accounts for 34.4% of sales, experienced a substantial 20.0% decline due to sluggish demand and delays in aviation CT system installations:
The company’s R&D costs increased to €2.6 million or 11.8% of net sales, up from 11.1% in Q1 2024, indicating continued investment in innovation despite challenging market conditions. Cash flow from operating activities declined significantly to €1.4 million from €3.0 million in the prior year period.
Strategic Initiatives
Detection Technology highlighted several strategic initiatives during the quarter, including the launch of a lead-free flat panel detector (X-Panel 2520z FOM) for dental imaging with advanced IGZO-TFT technology. The company also began pre-sales of an XL-sized a-Si-TFT flat panel detector optimized for high-energy industrial NDT applications.
Additionally, the company progressed with the ramp-up of its Indian manufacturing site to support its "Made in India" offering and continued to strengthen capabilities for EU Origin solutions, which could help mitigate geopolitical supply chain risks.
Forward-Looking Statements
The company’s outlook for the coming quarters shows mixed expectations across segments and regions. For Q2 2025, Detection Technology expects growth in the industrial and medical sectors, while the security sector is projected to decline:
Detection Technology revised its previous guidance of double-digit growth, now expecting stable year-on-year total net sales in Q2 and Q3 of 2025. The company cited exchange rate changes and security system deployment delays as the primary reasons for this revision.
Despite near-term challenges, Detection Technology maintained its medium-term financial targets of annual sales growth exceeding 10%, an operating margin (EBITA) of 15%, and an annual dividend or returned capital of 30-60%.
The company also acknowledged several risk factors, including geopolitical issues, new import tariffs, US-China relations, global economic challenges, healthcare reform, price competition, and the ongoing impact of the war in Ukraine.
Given the significant stock price decline following the presentation, investors appear concerned about the company’s ability to achieve its medium-term targets in light of the current market challenges and compressed margins.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.